The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains.
Wild type mumps viruses are highly neurotropic and a frequent cause of aseptic meningitis in unvaccinated humans. To test whether attenuated mumps viruses used in the manufacture of mumps vaccines have neurovirulent properties, a monkey neurovirulence safety test (MNVT) is performed. However, results with several mumps virus MNVTs have raised questions as to whether the test can reliably discriminate neurovirulent from nonneurovirulent mumps virus strains. Here, various mumps virus strains representing a wide range of neuropathogenicity were tested in a standardized MNVT. A trend of higher neurovirulence scores was observed in monkeys inoculated with wild type mumps virus versus vaccine strains, although differences were not statistically significant. Results indicated the need for further examination and refinement of the MNVT or for development of alternative MNVTs.
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. rubins@cber.fda.gov
S A
SA
Rubin
P J
PJ
Snoy
K E
KE
Wright
E G
EG
Brown
P
P
Reeve
J A
JA
Beeler
K M
KM
Carbone
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001921:Brain / Q000473:pathology / Q000821:virology; D002494:Central Nervous System Infections / Q000473:pathology / Q000821:virology; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D006801:Humans; D008253:Macaca mulatta; D009107:Mumps / Q000473:pathology / Q000821:virology; D009108:Mumps Vaccine; D009109:Mumps virus / Q000276:immunology / Q000472:pathogenicity*; D013045:Species Specificity; D014613:Vaccines, Attenuated / Q000009:adverse effects*; D014709:Vero Cells; D014774:Virulence
D000914:Antibodies, Viral; D009108:Mumps Vaccine; D014613:Vaccines, Attenuated